Burlington, United States
Hyku Biosciences, founded in 2021 and headquartered in the United States, is carving a niche within the Biopharma, Biotechnology, and Life Sciences sectors. The company's slogan, "Expanding the Boundaries of Covalent Therapies," captures its mission-driven approach to healthcare innovation.
With a focus on pioneering precise covalent targeting of disease-causing proteins, Hyku aims to shift traditional treatment paradigms and enhance patient outcomes. The company's recent $56.00M seed investment round in September 2023 highlights substantial backing from industry stalwarts, including Novartis Venture Fund, RA Capital Management, KB Investments, The Mark Foundation for Cancer Research, Eisai Innovation Inc, and Droia Oncology Ventures.
This infusion of capital not only underscores investor confidence in Hyku's groundbreaking approach but also positions the company to accelerate its development pipeline, potentially transforming the biopharmaceutical landscape.
